Suppr超能文献

胎儿纤连蛋白检测对早产入院的影响。

Impact of the fetal fibronectin assay on admissions for preterm labor.

作者信息

Joffe G M, Jacques D, Bemis-Heys R, Burton R, Skram B, Shelburne P

机构信息

Lovelace Medical Center, Albuquerque, NM 87108, USA.

出版信息

Am J Obstet Gynecol. 1999 Mar;180(3 Pt 1):581-6. doi: 10.1016/s0002-9378(99)70258-9.

Abstract

OBJECTIVE

The aim of the study was to determine whether use of the fetal fibronectin assay would decrease the number of admissions to labor and delivery for diagnosis and treatment of preterm labor.

STUDY DESIGN

A prospective cohort design was used to compare preterm labor admissions during a 12-month period of fetal fibronectin assay use (study) against a baseline period before fetal fibronectin assay was implemented as standard protocol. Patients coming to the physician's office or hospital with signs and symptoms of preterm labor had a sample obtained for fetal fibronectin assay per labeling criteria. Comparisons were made with the Mann-Whitney U test, independent Student t test, chi2 test, and Fisher exact test. P <.05 was considered significant.

RESULTS

There was no difference noted in the number of deliveries between the baseline and study years. During the study year 251 of 330 patients evaluated for preterm labor met study criteria and had the fetal fibronectin assay completed. Eight patients did not have fetal fibronectin assay results available because of specimen handling errors, leaving 243 subjects available for study. Compared with the baseline year, the study year had significantly fewer admissions for preterm labor, preterm labor admissions per patient, and prescriptions written for tocolytic agents. In addition, the length of stay per admitted patient was significantly reduced. The study population had no differences in neonatal outcomes from the baseline population in terms of deliveries at <35.0 weeks' gestation, number of admissions to the neonatal intensive care unit, neonatal intensive care unit length of stay, or days of ventilatory support per patient admitted to the neonatal intensive care unit.

CONCLUSIONS

Use of the fetal fibronectin assay resulted in significantly reduced preterm labor admissions, length of stay, and prescriptions for tocolytic agents. No negative impact on neonatal outcomes was observed. Reductions in admissions for preterm labor and in charges per admission resulted in approximately $486,000 saved during the study period. A trend toward increased corticosteroid administration (for neonates ultimately admitted to the neonatal intensive care unit) was noted.

摘要

目的

本研究旨在确定使用胎儿纤连蛋白检测是否会减少因早产诊断和治疗而入住分娩室的人数。

研究设计

采用前瞻性队列设计,将使用胎儿纤连蛋白检测的12个月期间(研究期)的早产入院情况与胎儿纤连蛋白检测作为标准方案实施前的基线期进行比较。出现早产体征和症状前来医生办公室或医院就诊的患者,根据标签标准采集样本进行胎儿纤连蛋白检测。采用Mann-Whitney U检验、独立样本t检验、卡方检验和Fisher精确检验进行比较。P<0.05被认为具有统计学意义。

结果

基线期和研究期的分娩数量没有差异。在研究期,330例接受早产评估的患者中有251例符合研究标准并完成了胎儿纤连蛋白检测。8例患者因标本处理错误未获得胎儿纤连蛋白检测结果,剩余243例受试者可供研究。与基线期相比,研究期早产入院人数、每位患者的早产入院次数以及开具的宫缩抑制剂处方显著减少。此外,每位入院患者的住院时间显著缩短。研究人群与基线人群相比,在妊娠<35.0周分娩、新生儿重症监护病房入院次数、新生儿重症监护病房住院时间或每位入住新生儿重症监护病房患者的通气支持天数方面,新生儿结局没有差异。

结论

使用胎儿纤连蛋白检测可显著减少早产入院人数、住院时间和宫缩抑制剂处方。未观察到对新生儿结局有负面影响。早产入院人数和每次入院费用的减少在研究期间节省了约48.6万美元。注意到(最终入住新生儿重症监护病房的新生儿)使用皮质类固醇有增加的趋势。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验